Tyrogenex is affiliated with Xcovery Holdings. It was founded by Sheridan (Sherry) Snyder through Biocatalyst International in partnership with Dr. Chris Liang. Through this partnership, Tyrogenex has developed a novel, patented cancer therapeutic, X-82. The compound, a dual VEGFR/PDGFR inhibitor, is being studies in a clinical trial for the treatment of advanced solid tumors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/19/14 | $15,000,000 | Series D |
Brace Pharma | undisclosed |
